<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36045680</PMID><DateCompleted><Year>2022</Year><Month>09</Month><Day>08</Day></DateCompleted><DateRevised><Year>2022</Year><Month>09</Month><Day>14</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1664-3224</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>Frontiers in immunology</Title><ISOAbbreviation>Front Immunol</ISOAbbreviation></Journal><ArticleTitle>Antibodies against the SARS-CoV-2 S1-RBD cross-react with dengue virus and hinder dengue pathogenesis.</ArticleTitle><Pagination><StartPage>941923</StartPage><MedlinePgn>941923</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">941923</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fimmu.2022.941923</ELocationID><Abstract><AbstractText>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread globally since December 2019. Several studies reported that SARS-CoV-2 infections may produce false-positive reactions in dengue virus (DENV) serology tests and vice versa. However, it remains unclear whether SARS-CoV-2 and DENV cross-reactive antibodies provide cross-protection against each disease or promote disease severity. In this study, we confirmed that antibodies against the SARS-CoV-2 spike protein and its receptor-binding domain (S1-RBD) were significantly increased in dengue patients compared to normal controls. In addition, anti-S1-RBD IgG purified from S1-RBD hyperimmune rabbit sera could cross-react with both DENV envelope protein (E) and nonstructural protein 1 (NS1). The potential epitopes of DENV E and NS1 recognized by these antibodies were identified by a phage-displayed random peptide library. In addition, DENV infection and DENV NS1-induced endothelial hyperpermeability <i>in vitro</i> were inhibited in the presence of anti-S1-RBD IgG. Passive transfer anti-S1-RBD IgG into mice also reduced prolonged bleeding time and decreased NS1 seral level in DENV-infected mice. Lastly, COVID-19 patients' sera showed neutralizing ability against dengue infection <i>in vitro</i>. Thus, our results suggest that the antigenic cross-reactivity between the SARS-CoV-2 S1-RBD and DENV can induce the production of anti-SARS-CoV-2 S1-RBD antibodies that cross-react with DENV which may hinder dengue pathogenesis.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 Cheng, Chao, Lai, Hsieh, Wang, Wan, Huang, Chuang, Chuang and Yeh.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cheng</LastName><ForeName>Yi-Ling</ForeName><Initials>YL</Initials><AffiliationInfo><Affiliation>Department of Medical Laboratory Science and Biotechnology, College of Medicine, National Cheng Kung University, Tainan, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chao</LastName><ForeName>Chiao-Hsuan</ForeName><Initials>CH</Initials><AffiliationInfo><Affiliation>Department of Medical Laboratory Science and Biotechnology, College of Medicine, National Cheng Kung University, Tainan, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lai</LastName><ForeName>Yen-Chung</ForeName><Initials>YC</Initials><AffiliationInfo><Affiliation>Department of Medical Laboratory Science and Biotechnology, College of Medicine, National Cheng Kung University, Tainan, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hsieh</LastName><ForeName>Kun-Han</ForeName><Initials>KH</Initials><AffiliationInfo><Affiliation>Department of Medical Laboratory Science and Biotechnology, College of Medicine, National Cheng Kung University, Tainan, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Jen-Ren</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>Department of Medical Laboratory Science and Biotechnology, College of Medicine, National Cheng Kung University, Tainan, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wan</LastName><ForeName>Shu-Wen</ForeName><Initials>SW</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, College of Medicine, National Cheng Kung University, Tainan, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Hong-Jyun</ForeName><Initials>HJ</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, College of Medicine, National Cheng Kung University, Tainan, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chuang</LastName><ForeName>Yung-Chun</ForeName><Initials>YC</Initials><AffiliationInfo><Affiliation>Department of Medical Laboratory Science and Biotechnology, College of Medicine, National Cheng Kung University, Tainan, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Leadgene Biomedical, Inc., Tainan, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chuang</LastName><ForeName>Woei-Jer</ForeName><Initials>WJ</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Biology, College of Medicine, National Cheng Kung University, Tainan, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yeh</LastName><ForeName>Trai-Ming</ForeName><Initials>TM</Initials><AffiliationInfo><Affiliation>Department of Medical Laboratory Science and Biotechnology, College of Medicine, National Cheng Kung University, Tainan, Taiwan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>08</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Immunol</MedlineTA><NlmUniqueID>101560960</NlmUniqueID><ISSNLinking>1664-3224</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017361">Viral Nonstructural Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000657845">spike protein, SARS-CoV-2</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003715" MajorTopicYN="Y">Dengue</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003716" MajorTopicYN="Y">Dengue Virus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007074" MajorTopicYN="N">Immunoglobulin G</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011817" MajorTopicYN="N">Rabbits</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064370" MajorTopicYN="N">Spike Glycoprotein, Coronavirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017361" MajorTopicYN="N">Viral Nonstructural Proteins</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">antibody-dependent enhancement</Keyword><Keyword MajorTopicYN="N">dengue virus</Keyword><Keyword MajorTopicYN="N">diagnosis</Keyword></KeywordList><CoiStatement>YC-C is employed by Leadgene Biomedical, Inc. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationship that could be considered a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>5</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>7</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>1</Day><Hour>2</Hour><Minute>15</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36045680</ArticleId><ArticleId IdType="pmc">PMC9420930</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2022.941923</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Vabret N, Britton GJ, Gruber C, Hegde S, Kim J, Kuksin M, et al. . Immunology of COVID-19: Current state of the science. Immunity (2020) 52(6):910&#x2013;41. doi:&#xa0;10.1016/j.immuni.2020.05.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2020.05.002</ArticleId><ArticleId IdType="pmc">PMC7200337</ArticleId><ArticleId IdType="pubmed">32505227</ArticleId></ArticleIdList></Reference><Reference><Citation>Synowiec A, Szczepanski A, Barreto-Duran E, Lie LK, Pyrc K. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): A systemic infection. Clin Microbiol Rev (2021) 34(2):e00133&#x2013;20. doi:&#xa0;10.1128/CMR.00133-20</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CMR.00133-20</ArticleId><ArticleId IdType="pmc">PMC7849242</ArticleId><ArticleId IdType="pubmed">33441314</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Y, Yang C, Xu XF, Xu W, Liu SW. Structural and functional properties of SARS-CoV-2 spike protein: Potential antivirus drug development for COVID-19. Acta Pharmacol Sin (2020) 41(9):1141&#x2013;9. doi:&#xa0;10.1038/s41401-020-0485-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41401-020-0485-4</ArticleId><ArticleId IdType="pmc">PMC7396720</ArticleId><ArticleId IdType="pubmed">32747721</ArticleId></ArticleIdList></Reference><Reference><Citation>Premkumar L, Segovia-Chumbez B, Jadi R, Martinez DR, Raut R, Markmann A, et al. . The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients. Sci Immunol (2020) 5(48):eabc8413. doi:&#xa0;10.1126/sciimmunol.abc841</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abc841</ArticleId><ArticleId IdType="pmc">PMC7292505</ArticleId><ArticleId IdType="pubmed">32527802</ArticleId></ArticleIdList></Reference><Reference><Citation>Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell (2020) 181(2):281&#x2013;92. doi:&#xa0;10.1016/j.cell.2020.02.058</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.02.058</ArticleId><ArticleId IdType="pmc">PMC7102599</ArticleId><ArticleId IdType="pubmed">32155444</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao X. COVID-19: immunopathology and its implications for therapy. Nat Rev Immunol (2020) 20(5):269&#x2013;70. doi:&#xa0;10.1038/s41577-020-0308-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-020-0308-3</ArticleId><ArticleId IdType="pmc">PMC7143200</ArticleId><ArticleId IdType="pubmed">32273594</ArticleId></ArticleIdList></Reference><Reference><Citation>Nath H, Mallick A, Roy S, Sukla S, Basu K, De A, et al. . Archived dengue serum samples produced false-positive results in SARS-CoV-2 lateral flow-based rapid antibody tests. J Med Microbiol (2021) 70(6):1369. doi:&#xa0;10.1099/jmm.0.001369</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/jmm.0.001369</ArticleId><ArticleId IdType="pmc">PMC8459096</ArticleId><ArticleId IdType="pubmed">34110279</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan G, Lee CK, Lam LTM, Yan B, Chua YX, Lim AYN, et al. . Covert COVID-19 and false-positive dengue serology in Singapore. Lancet Infect Dis (2020) 20(5):536. doi:&#xa0;10.1016/S1473-3099(20)30158-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(20)30158-4</ArticleId><ArticleId IdType="pmc">PMC7128937</ArticleId><ArticleId IdType="pubmed">32145189</ArticleId></ArticleIdList></Reference><Reference><Citation>Santoso MS, Masyeni S, Haryanto S, Yohan B, Hibberd ML, Sasmono RT. Assessment of dengue and COVID-19 antibody rapid diagnostic tests cross-reactivity in Indonesia. Virol J (2021) 18(1):54. doi:&#xa0;10.1186/s12985-021-01522-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12985-021-01522-2</ArticleId><ArticleId IdType="pmc">PMC7948652</ArticleId><ArticleId IdType="pubmed">33706767</ArticleId></ArticleIdList></Reference><Reference><Citation>Khairunisa SQ, Amarullah IH, Churrotin S, Fitria AL, Amin M, Lusida MI, et al. . Potential misdiagnosis between COVID-19 and dengue infection using rapid serological test. Infect Dis Rep (2021) 13(2):540&#x2013;51. doi:&#xa0;10.3390/idr13020050</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/idr13020050</ArticleId><ArticleId IdType="pmc">PMC8293083</ArticleId><ArticleId IdType="pubmed">34200159</ArticleId></ArticleIdList></Reference><Reference><Citation>Lustig Y, Keler S, Kolodny R, Ben-Tal N, Atias-Varon D, Shlush E, et al. . Potential antigenic cross-reactivity between SARS-CoV-2 and dengue viruses. Clin Infect Dis (2020) 73(7):e2444&#x2013;9. doi:&#xa0;10.1093/cid/ciaa1207</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa1207</ArticleId><ArticleId IdType="pmc">PMC7454334</ArticleId><ArticleId IdType="pubmed">32797228</ArticleId></ArticleIdList></Reference><Reference><Citation>Messina JP, Brady OJ, Golding N, Kraemer MUG, Wint GRW, Ray SE, et al. . The current and future global distribution and population at risk of dengue. Nat Microbiol (2019) 4(9):1508&#x2013;15. doi:&#xa0;10.1038/s41564-019-0476-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41564-019-0476-8</ArticleId><ArticleId IdType="pmc">PMC6784886</ArticleId><ArticleId IdType="pubmed">31182801</ArticleId></ArticleIdList></Reference><Reference><Citation>Halstead SB. Antibody, macrophages, dengue virus infection, shock, and hemorrhage: A pathogenetic cascade. Rev Infect Dis (1989) 11(Suppl 4):S830&#x2013;9. doi:&#xa0;10.1093/clinids/11.supplement_4.s830</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/clinids/11.supplement_4.s830</ArticleId><ArticleId IdType="pubmed">2665015</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulrich H, Pillat MM, Tarnok A. Dengue fever, COVID-19 (SARS-CoV-2), and antibody-dependent enhancement (ADE): A perspective. Cytometry A (2020) 97(7):662&#x2013;7. doi:&#xa0;10.1002/cyto.a.24047</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cyto.a.24047</ArticleId><ArticleId IdType="pmc">PMC7300451</ArticleId><ArticleId IdType="pubmed">32506725</ArticleId></ArticleIdList></Reference><Reference><Citation>Henchal EA, Putnak JR. The dengue viruses. Clin Microbiol Rev (1990) 3(41):376&#x2013;96. doi:&#xa0;10.1128/CMR.3.4.376</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CMR.3.4.376</ArticleId><ArticleId IdType="pmc">PMC358169</ArticleId><ArticleId IdType="pubmed">2224837</ArticleId></ArticleIdList></Reference><Reference><Citation>Avirutnan P, Punyadee N, Noisakran S, Komoltri C, Thiemmeca S, Auethavornanan K, et al. . Vascular leakage in severe dengue virus infections: A potential role for the nonstructural viral protein NS1 and complement. J Infect Dis (2006) 193(8):1078&#x2013;88. doi:&#xa0;10.1086/500949</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/500949</ArticleId><ArticleId IdType="pubmed">16544248</ArticleId></ArticleIdList></Reference><Reference><Citation>Beatty PR, Puerta-Guardo H, Killingbeck SS, Glasner DR, Hopkins K, Harris E. Dengue virus NS1 triggers endothelial permeability and vascular leak that is prevented by NS1 vaccination. Sci Transl Med (2015) 7(304):304ra141&#x2013;304ra141. doi:&#xa0;10.1126/scitranslmed.aaa3787</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aaa3787</ArticleId><ArticleId IdType="pubmed">26355030</ArticleId></ArticleIdList></Reference><Reference><Citation>Modhiran N, Watterson D, Muller DA, Panetta AK, Sester DP, Liu L, et al. . Dengue virus NS1 protein activates cells via toll-like receptor 4 and disrupts endothelial cell monolayer integrity. Sci Transl Med (2015) 7(304):304ra142. doi:&#xa0;10.1126/scitranslmed.aaa3863</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aaa3863</ArticleId><ArticleId IdType="pubmed">26355031</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas SJ. NS1: A corner piece in the dengue pathogenesis puzzle? Sci Transl Med (2015) 7(304):304fs37. doi:&#xa0;10.1126/scitranslmed.aad1255</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aad1255</ArticleId><ArticleId IdType="pubmed">26355028</ArticleId></ArticleIdList></Reference><Reference><Citation>Martina BE, Koraka P, Osterhaus AD. Dengue virus pathogenesis: An integrated view. Clin Microbiol Rev (2009) 22(4):564&#x2013;81. doi:&#xa0;10.1128/CMR.00035-09</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CMR.00035-09</ArticleId><ArticleId IdType="pmc">PMC2772360</ArticleId><ArticleId IdType="pubmed">19822889</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothman AL. Dengue: defining protective versus pathologic immunity. J Clin Invest (2004) 113(7):946&#x2013;51. doi:&#xa0;10.1172/JCI21512</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI21512</ArticleId><ArticleId IdType="pmc">PMC379334</ArticleId><ArticleId IdType="pubmed">15057297</ArticleId></ArticleIdList></Reference><Reference><Citation>Lei HY, Yeh TM, Liu HS, Lin YS, Chen SH, Liu CC. Immunopathogenesis of dengue virus infection. J BioMed Sci (2001) 8(51):377&#x2013;88. doi:&#xa0;10.1007/BF02255946</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF02255946</ArticleId><ArticleId IdType="pubmed">11549879</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee WS, Wheatley AK, Kent SJ, DeKosky BJ. Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies. Nat Microbiol (2020) 5(10):1185&#x2013;91. doi:&#xa0;10.1038/s41564-020-00789-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41564-020-00789-5</ArticleId><ArticleId IdType="pubmed">32908214</ArticleId></ArticleIdList></Reference><Reference><Citation>Nath H, Mallick A, Roy S, Sukla S, Biswas S. Computational modelling supports that dengue virus envelope antibodies can bind to SARS-CoV-2 receptor binding sites: Is pre-exposure to dengue virus protective against COVID-19 severity? Comput Struct Biotechnol J (2021) 19:459&#x2013;66. doi:&#xa0;10.1016/j.csbj.2020.12.037</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.csbj.2020.12.037</ArticleId><ArticleId IdType="pmc">PMC7770470</ArticleId><ArticleId IdType="pubmed">33391633</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen HR, Chao CH, Liu CC, Ho TS, Tsai HP, Perng GC, et al. . Macrophage migration inhibitory factor is critical for dengue NS1-induced endothelial glycocalyx degradation and hyperpermeability. PloS Pathog (2018) 14(4):e1007033. doi:&#xa0;10.1371/journal.ppat.1007033</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1007033</ArticleId><ArticleId IdType="pmc">PMC6044858</ArticleId><ArticleId IdType="pubmed">29702687</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai YC, Cheng YW, Chao CH, Chang YY, Chen CD, Tsai WJ, et al. . Antigenic cross-reactivity between SARS-CoV-2 S1-RBD and its receptor ACE2. Front Immunol (2022) 13:868724. doi:&#xa0;10.3389/fimmu.2022.868724</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.868724</ArticleId><ArticleId IdType="pmc">PMC9114768</ArticleId><ArticleId IdType="pubmed">35603169</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen LC, Shyu HW, Lin HM, Lei HY, Lin YS, Liu HS, et al. . Dengue virus induces thrombomodulin expression in human endothelial cells and monocytes in vitro . J Infect (2009) 58(5):368&#x2013;74. doi:&#xa0;10.1016/j.jinf.2009.02.018</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2009.02.018</ArticleId><ArticleId IdType="pubmed">19307023</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang SW, Tai CH, Hsu YM, Cheng D, Hung SJ, Chai KM, et al. . Assessing the application of a pseudovirus system for emerging SARS-CoV-2 and re-emerging avian influenza virus H5 subtypes in vaccine development. BioMed J (2020) 43(4):375&#x2013;87. doi:&#xa0;10.1016/j.bj.2020.06.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bj.2020.06.003</ArticleId><ArticleId IdType="pmc">PMC7274974</ArticleId><ArticleId IdType="pubmed">32611537</ArticleId></ArticleIdList></Reference><Reference><Citation>Tien SM, Chang PC, Lai YC, Chuang YC, Tseng CK, Kao YS, et al. . Therapeutic efficacy of humanized monoclonal antibodies targeting dengue virus nonstructural protein 1 in the mouse model. PLoS Pathog (2022) 18(4):e1010469. doi:&#xa0;10.1371/journal.ppat.1010469</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1010469</ArticleId><ArticleId IdType="pmc">PMC9053773</ArticleId><ArticleId IdType="pubmed">35486576</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen HR, Chuang YC, Lin YS, Liu HS, Liu CC, Perng GC, et al. . Dengue virus nonstructural protein 1 induces vascular leakage through macrophage migration inhibitory factor and autophagy. PLoS Negl Trop Dis (2016) 10(7):e0004828. doi:&#xa0;10.1371/journal.pntd.0004828</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pntd.0004828</ArticleId><ArticleId IdType="pmc">PMC4943727</ArticleId><ArticleId IdType="pubmed">27409803</ArticleId></ArticleIdList></Reference><Reference><Citation>Puerta-Guardo H, Glasner DR, Harris E. Dengue virus NS1 disrupts the endothelial glycocalyx, leading to hyperpermeability. PLoS Pathog (2016) 12(7):e1005738. doi:&#xa0;10.1371/journal.ppat.1005738</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1005738</ArticleId><ArticleId IdType="pmc">PMC4944995</ArticleId><ArticleId IdType="pubmed">27416066</ArticleId></ArticleIdList></Reference><Reference><Citation>Glasner DR, Ratnasiri K, Puerta-Guardo H, Espinosa DA, Beatty PR, Harris E. Dengue virus NS1 cytokine-independent vascular leak is dependent on endothelial glycocalyx components. PLoS Pathog (2017) 13(11):e1006673. doi:&#xa0;10.1371/journal.ppat.1006673</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1006673</ArticleId><ArticleId IdType="pmc">PMC5679539</ArticleId><ArticleId IdType="pubmed">29121099</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai YC, Chuang YC, Liu CC, Ho TS, Lin YS, Anderson R, et al. . Antibodies against modified NS1 wing domain peptide protect against dengue virus infection. Sci Rep (2017) 7(1):6975. doi:&#xa0;10.1038/s41598-017-07308-3.Huang</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-07308-3.Huang</ArticleId><ArticleId IdType="pmc">PMC5539099</ArticleId><ArticleId IdType="pubmed">28765561</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang KJ, Yang YC, Lin YS, Huang JH, Liu HS, Yeh TM, et al. . The dual-specific binding of dengue virus and target cells for the antibody-dependent enhancement of dengue virus infection. J Immunol (2006) 176(5):2825&#x2013;32. doi:&#xa0;10.4049/jimmunol.176.5.2825</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.176.5.2825</ArticleId><ArticleId IdType="pubmed">16493039</ArticleId></ArticleIdList></Reference><Reference><Citation>Wan SW, Chen PW, Chen CY, Lai YC, Chu YT, Hung CY, et al. . Therapeutic effects of monoclonal antibody against dengue virus NS1 in a STAT1 knockout mouse model of dengue infection. J Immunol (2017) 199(8):2834&#x2013;44. doi:&#xa0;10.4049/jimmunol.1601523</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1601523</ArticleId><ArticleId IdType="pubmed">28904127</ArticleId></ArticleIdList></Reference><Reference><Citation>Vanroye F, Bossche DVD, Brosius I, Tack B, Esbroeck MV, Jacobs J. COVID-19 antibody detecting rapid diagnostic tests show high cross-reactivity when challenged with pre-pandemic malaria, schistosomiasis and dengue samples. Diagn. (Basel) (2021) 11(7):1163. doi:&#xa0;10.3390/diagnostics11071163</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/diagnostics11071163</ArticleId><ArticleId IdType="pmc">PMC8305106</ArticleId><ArticleId IdType="pubmed">34202195</ArticleId></ArticleIdList></Reference><Reference><Citation>Bokhari S, Mahmood F, Bokhari S. Case report: Diagnosis of COVID-19 versus tropical diseases in Pakistan. Am J Trop Med Hyg (2020) 103(1):77&#x2013;8. doi:&#xa0;10.4269/ajtmh.20-0356</Citation><ArticleIdList><ArticleId IdType="doi">10.4269/ajtmh.20-0356</ArticleId><ArticleId IdType="pmc">PMC7263525</ArticleId><ArticleId IdType="pubmed">32372752</ArticleId></ArticleIdList></Reference><Reference><Citation>Nunthavichitra S, Prapaso S, Luvira V, Muangnoicharoen S, Leaungwutiwong P, Piyaphanee W. Case report: COVID-19 presenting as acute undifferentiated febrile illness-a tropical world threat. Am J Trop Med Hyg (2020) 103(1):83&#x2013;5. doi:&#xa0;10.4269/ajtmh.20-0440</Citation><ArticleIdList><ArticleId IdType="doi">10.4269/ajtmh.20-0440</ArticleId><ArticleId IdType="pmc">PMC7356458</ArticleId><ArticleId IdType="pubmed">32419694</ArticleId></ArticleIdList></Reference><Reference><Citation>Rana MS, Usman M, Alam MM, Ikram A, Salman M, Umair M. Impact of previous SARS-CoV-2 infection on the rate of mortality in dengue. a preliminary report from Pakistan. J Infect (2022) 84(5):722&#x2013;46. doi:&#xa0;10.1016/j.jinf.2022.01.027</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2022.01.027</ArticleId><ArticleId IdType="pmc">PMC8783977</ArticleId><ArticleId IdType="pubmed">35081438</ArticleId></ArticleIdList></Reference><Reference><Citation>Ravikumar N, Randhawa MS, Nallasamy K, Angurana SK, Kumar M, Mohi GK, et al. . Impact of recent SARS-CoV-2 infection on the course and severity of dengue in children: A prospective observational study from north India. Am J Trop Med Hyg (2021) 105(3):751&#x2013;5. doi:&#xa0;10.4269/ajtmh.21-0586</Citation><ArticleIdList><ArticleId IdType="doi">10.4269/ajtmh.21-0586</ArticleId><ArticleId IdType="pmc">PMC8592356</ArticleId><ArticleId IdType="pubmed">34339386</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicolete VC, Rodrigues PT, Johansen IC, Corder RM, Tonini J, Cardoso MA, et al. . Interacting epidemics in Amazonian Brazil: Prior dengue infection associated with increased coronavirus disease 2019 (COVID-19) risk in a population-based cohort study. Clin Infect Dis (2021) 73(11):2045&#x2013;54. doi:&#xa0;10.1093/cid/ciab410</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciab410</ArticleId><ArticleId IdType="pmc">PMC8135953</ArticleId><ArticleId IdType="pubmed">33956939</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Qushayri AE, Kamel AMA, Reda A, Ghozy S. Does dengue and COVID-19 co-infection have worse outcomes? A systematic review of current evidence. Rev Med Virol (2022) 1&#x2013;7:e2339. doi:&#xa0;10.1002/rmv.2339</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rmv.2339</ArticleId><ArticleId IdType="pmc">PMC9111070</ArticleId><ArticleId IdType="pubmed">35213764</ArticleId></ArticleIdList></Reference><Reference><Citation>Prapty C, Rahmat R, Araf Y, Shounak SK, Noor AA, Rahaman TI, et al. . SARS-CoV-2 and dengue virus co-infection: Epidemiology, pathogenesis, diagnosis, treatment, and management. Rev Med Virol (2022) 1&#x2013;11:e2340. doi:&#xa0;10.1002/rmv.2340</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rmv.2340</ArticleId><ArticleId IdType="pmc">PMC9111128</ArticleId><ArticleId IdType="pubmed">35238422</ArticleId></ArticleIdList></Reference><Reference><Citation>Crill WD, Roehrig JT. Monoclonal antibodies that bind to domain III of dengue virus e glycoprotein are the most efficient blockers of virus adsorption to vero cells. J Virol (2001) 75(16):7769&#x2013;73. doi:&#xa0;10.1128/JVI.75.16.7769-7773.2001</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.75.16.7769-7773.2001</ArticleId><ArticleId IdType="pmc">PMC115016</ArticleId><ArticleId IdType="pubmed">11462053</ArticleId></ArticleIdList></Reference><Reference><Citation>Costin JM, Zaitseva E, Kahle KM, Nicholson CO, Rowe DK, Graham AS, et al. . Mechanistic study of broadly neutralizing human monoclonal antibodies against dengue virus that target the fusion loop. J Virol (2013) 87(1):52&#x2013;66. doi:&#xa0;10.1128/JVI.02273-12</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02273-12</ArticleId><ArticleId IdType="pmc">PMC3536401</ArticleId><ArticleId IdType="pubmed">23077306</ArticleId></ArticleIdList></Reference><Reference><Citation>Pokidysheva E, Zhang Y, Battisti AJ, Bator-Kelly CM, Chipman PR, Xiao C, et al. . Cryo-EM reconstruction of dengue virus in complex with the carbohydrate recognition domain of DC-SIGN. Cell (2006) 124(3):485&#x2013;93. doi:&#xa0;10.1016/j.cell.2005.11.042</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2005.11.042</ArticleId><ArticleId IdType="pubmed">16469696</ArticleId></ArticleIdList></Reference><Reference><Citation>Alen MM, Dallmeier K, Balzarini J, Neyts J, Schols D. Crucial role of the n-glycans on the viral e-envelope glycoprotein in DC-SIGN-mediated dengue virus infection. Antiviral Res (2012) 96(3):280&#x2013;7. doi:&#xa0;10.1016/j.antiviral.2012.10.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2012.10.007</ArticleId><ArticleId IdType="pubmed">23124109</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen HR, Lai YC, Yeh TM. Dengue virus non-structural protein 1: a pathogenic factor, therapeutic target, and vaccine candidate. J BioMed Sci (2018) 25(1):58. doi:&#xa0;10.1186/s12929-018-0462-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12929-018-0462-0</ArticleId><ArticleId IdType="pmc">PMC6057007</ArticleId><ArticleId IdType="pubmed">30037331</ArticleId></ArticleIdList></Reference><Reference><Citation>Glasner DR, Puerta-Guardo H, Beatty PR, Harris E. The good, the bad, and the shocking: The multiple roles of dengue virus nonstructural protein 1 in protection and pathogenesis. Annu Rev Virol (2018) 5(1):227&#x2013;53. doi:&#xa0;10.1146/annurev-virology-101416-041848</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-virology-101416-041848</ArticleId><ArticleId IdType="pmc">PMC6311996</ArticleId><ArticleId IdType="pubmed">30044715</ArticleId></ArticleIdList></Reference><Reference><Citation>Nath H, Mallick A, Roy S, Kayal T, Ranjan S, Sengupta S, et al. . COVID-19 serum can be cross-reactive and neutralizing against the dengue virus, as observed by the dengue virus neutralization test. Int J Infect Dis (2022) 122:576&#x2013;84. doi:&#xa0;10.1016/j.ijid.2022.07.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2022.07.013</ArticleId><ArticleId IdType="pmc">PMC9262656</ArticleId><ArticleId IdType="pubmed">35811081</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>